



CERTIFICATE OF MAILING

TFW  
1645

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an Envelope addressed to: Mail Stop Disclosure Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or:

Date: 1/30/2007

By: [Signature]  
Winsome A. St. Rose

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:	)
Russell Gene Higuchi, et al.	) EXAMINER:
SERIAL NO.: 10/552,641	) ART UNIT: 1645
FILED: OCTOBER 7, 2005	) Confirmation No. 1928
FOR: ASSOCIATIONS OF POLYMORPHISMS IN THE FRZB GENE WITH OBESITY AND OSTEOPOROSIS	) DOCKET No: 21634-US2

INFORMATION DISCLOSURE STATEMENT

Mail Stop Disclosure.  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:


Applicant submits herewith a Form-1449, in compliance with the duty of disclosure requirements of 37 C.F.R. §1.56, 1.97 and 1.98, listing accompanying documents that may be considered material to the examination of this application. This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits, whichever event occurs last. No certification or fee is therefore required under 37 C.F.R. § 1.97(b). However, should the Commissioner determine that fees are due in order for the Information Disclosure Statement to be considered at this stage, the Commissioner is hereby authorized to charge any fee deficiency, or credit any overpayment, to Deposit Account No. 50-0812.

This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

Consideration of the cited documents and making the same of record in the prosecution of the above-identified application is respectfully requested.


Respectfully submitted,

Date: 1/29/07

  
Rhea C. Nersesian  
Reg. No. 55,488

Correspondence Address:  
Roche Molecular Systems, Inc  
1145 Atlantic Avenue  
Alameda, CA 94501  
Tele: (510) 814-2800  
Fax: (510) 814-2973

Substitute for Form 1449/PTO		<b>Complete if known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT PTO-1449</b>		Application Number	10/552,641
		Filing Date	October 7, 2005
		First Named Inventor	Russell Gene Higuchi
		Group Art Unit	1645
		Examiner Name	Unassigned
		Attorney Docket No.	21634-US2
Sheet	of	Date Submitted	Feb 2, 2007



## U.S. PATENT DOCUMENTS

Examiner Initials	Cite No	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YY	Pages, Columns, lines Where relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			
	1	6,479,242	B1	Guo, et al.	11-12-02	
	2	US 2002/0182616	A1	Wuhlestedt, et al.	12-05-02	
	3	US 2002/0182622	A1	Nakamura, et al.	12-05-02	

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YY	Pages, Columns, lines Where relevant Passages or Relevant Figures Appear	T
		Country Code	Number	Kind Code				
	4	WO	02/083839	A2	MOTOROLA, INC	10-24-02		

## OTHER PRIOR ART - NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the items (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published	T
	5	ACUÑA, G., et al., (2002), "Pharmacogenetic analysis of adverse drug effect reveals genetic variant for susceptibility to liver toxicity", <i>The Pharmacogenomics Journal</i> , 2: 227-234	
	6	GERMER, S., et al., (2000), "High-Throughput SNP Allele-Frequency Determination in Pooled DNA Samples by Kinetic PCR", <i>Genomic Research</i> , 10: 258-266	
	7	LEYNS, L., et al., (1997), "FRZB-1 is a secreted antagonist of Wnt Signaling Expressed in the Spemann Organizer", <i>Cell</i> , 88: 747-756	
	8	SCHUMANN, H., et al., (2000), "Expression of secreted frizzled related proteins 3 and 4 in human ventricular myocardium correlates with apoptosis related gene expression", <i>Cardiovascular Research</i> 45: 720-728	

Examiner's Signature	Date Considered
-------------------------	--------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.